Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia

Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia

Abstract Background Despite advances in targeted agent development, effective treatment of acute myeloid leukemia (AML) remains a major clinical challenge. The B-cell lymphoma-2 (BCL-2) inhibitor exhibited promising clinical activity in AML, acute lymphoblastic leukemia (ALL) and diffuse large B-cel...

Full description

Bibliographic Details
Main Authors: Wenwen Wei, Shujuan Huang, Qing Ling, Shihui Mao, Yu Qian, Wenle Ye, Fenglin Li, Jiajia Pan, Xiangjie Lin, Jiansong Huang, Xin Huang, Yifan Zhai, Jie Sun, Jie Jin
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Journal of Translational Medicine
Subjects:
Acute myeloid leukemia
Homoharringtonine
APG-2575
MCL-1
GSK3β
Online Access:https://doi.org/10.1186/s12967-022-03497-2

Internet

https://doi.org/10.1186/s12967-022-03497-2

Similar Items